At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 92 enrolled
Drug / intervention
Ketorolac 30 Mg +1 moredrug
Likely dose
Ketorolac 30 Mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dosing of Ketorolac Impacts Post-cesarean paiN manaGemenet (KING): A Randomized Controlled Trial
In Brief
A Phase 4 clinical trial evaluating Ketorolac 30 Mg and Ketorolac 60 Mg for Post Cesarean Pain. Completed, enrolled 92 participants across 1 site.
Detailed Summary
This is a randomized controlled single blinded trial to compare the morphine milligram equivalents (MME) use in the first 24 hours postoperatively after cesarean section in patients receiving a single dose of 30 mg intravenous ketorolac vs. 60 mg intravenous ketorolac in the operating room after the end of surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost Cesarean Pain
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedFeb 2022
Enrollment StartJun 2022
Primary CompletionNov 2023
TodayJul 2026
First PostedFeb 21, 2022
Enrollment StartJun 8, 2022
Primary CompletionNov 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.4 years ago
Interventions
Ketorolac 30 Mgdrug
Participants will receive single dose of intravenous (IV) Ketorolac 30mg
Ketorolac 60 Mgdrug
Participants will receive single dose of intravenous (IV) Ketorolac 60mg